Radioimmunotherapy of Metastatic Breast Cancer Using Radiolabeled Tumor Specific Antibodies.
NEW YORK UNIV MEDICAL CENTER NY
Pagination or Media Count:
Over the last year, we have worked to obtain a humanized version of the BrE-3 monoclonal antibody to have available for clinical trial. The humanized BrE-3 is now approved by the FDA and we are ready to start a radioimaging trial of 111In MX-DTPA huBrE-3 in patients with metastatic breast cancer. In the laboratory we are using the mouse model to conduct experiments combining chemotherapy with radio immunotherapy. We have performed studies evaluating the feasibility and efficacy of a continuous infusion of the topoisomerase 1 inhibitor, topotecan, in mice. We have demonstrated an antitumor effect of topotecan. Topotecan was successfully administered by continuous infusion in Alzet pumps. We are combining topotecan with IL-1 and exploring toxicity and efficacy. Our next set of experiments will incorporate radio immunotherapy into this system.
- Medicine and Medical Research
- Anatomy and Physiology